Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATLCAR.kappa.28
- Development stage
- Phase 1
- Lead developer
- Baylor College of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
ATLCAR.kappa.28 is an autologous chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of B-cell malignancies that express the immunoglobulin kappa (κ) light chain. This second-generation CAR construct consists of a single-chain variable fragment (scFv) derived from a κ-specific monoclonal antibody, which is fused to a CD28 costimulatory domain and a CD3ζ signaling domain. Unlike pan-B-cell therapies targeting CD19, ATLCAR.kappa.28 specifically targets the light chain restriction of the malignant clone. This approach is designed to eliminate κ-positive neoplastic B-cells while sparing normal λ-positive B-cells, potentially mitigating the severity of B-cell aplasia and associated hypogammaglobulinemia. The therapy is currently being evaluated in clinical trials for patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
- Other names
- Autologous kappa-chain chimeric receptor T cellsKappa-specific CAR-T cellsCAR.kappa-T cells
02
Targets
CD247 (T-cell surface glycoprotein CD3 epsilon chain)Immunoglobulin light chainCD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on ATLCAR.kappa.28.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATLCAR.kappa.28.